HDL-Based Therapy: Vascular Protection at All Stages

It is known that lipid metabolism disorders are involved in a wide range of pathologies. These pathologies include cardiovascular, metabolic, neurodegenerative diseases, and even cancer. All these diseases lead to serious health consequences, which makes it impossible to ignore them. Unfortunately, these diseases most often have a complex pathogenesis, which makes it difficult to study them and, in particular, diagnose and treat them. HDL is an important part of lipid metabolism, performing many functions under normal conditions. One of such functions is the maintaining of the reverse cholesterol transport. These functions are also implicated in pathology development. Thus, HDL contributes to vascular protection, which has been demonstrated in various conditions: Alzheimer’s disease, atherosclerosis, etc. Many studies have shown that serum levels of HDL cholesterol correlate negatively with CV risk. With these data, HDL-C is a promising therapeutic target. In this manuscript, we reviewed HDL-based therapeutic strategies that are currently being used or may be developed soon.

[1]  Ren Gong,et al.  Beneficial effects of high-density lipoprotein (HDL) on stent biocompatibility and the potential value of HDL infusion therapy following percutaneous coronary intervention , 2022, Medicine.

[2]  P. Magnusson,et al.  The Use of Monoclonal Antibody-Based Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia , 2022, Cureus.

[3]  M. Schindewolf,et al.  Inflammatory Mediators in Atherosclerotic Vascular Remodeling , 2022, Frontiers in Cardiovascular Medicine.

[4]  N. Maddu,et al.  Role of Lipoproteins in the Pathophysiology of Breast Cancer , 2022, Membranes.

[5]  K. Cho The Current Status of Research on High-Density Lipoproteins (HDL): A Paradigm Shift from HDL Quantity to HDL Quality and HDL Functionality , 2022, International journal of molecular sciences.

[6]  G. Marsche,et al.  Dietary Strategies to Improve Cardiovascular Health: Focus on Increasing High-Density Lipoprotein Functionality , 2021, Frontiers in Nutrition.

[7]  K. Socha,et al.  Mercury Content in Dietary Supplements From Poland Containing Ingredients of Plant Origin: A Safety Assessment , 2021, Frontiers in Pharmacology.

[8]  E. Lutgens,et al.  Apolipoprotein A1 deficiency in mice primes bone marrow stem cells for T cell lymphopoiesis , 2021, Journal of cell science.

[9]  G. Ferretti,et al.  High density lipoproteins and oxidative stress in breast cancer , 2021, Lipids in health and disease.

[10]  L. Kasselman,et al.  Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target , 2021, Metabolites.

[11]  K. Courneya,et al.  Effects of Exercise on Cardiorespiratory Fitness and Biochemical Progression in Men With Localized Prostate Cancer Under Active Surveillance: The ERASE Randomized Clinical Trial. , 2021, JAMA oncology.

[12]  C. Ayers,et al.  Regional adiposity, cardiorespiratory fitness, and left ventricular strain: an analysis from the Dallas Heart Study , 2021, Journal of Cardiovascular Magnetic Resonance.

[13]  K. Rye,et al.  High Density Lipoproteins and Diabetes , 2021, Cells.

[14]  A. Krętowski,et al.  Recent Highlights of Research on miRNAs as Early Potential Biomarkers for Cardiovascular Complications of Type 2 Diabetes Mellitus , 2021, International journal of molecular sciences.

[15]  A. Remaley,et al.  Apolipoprotein Mimetic Peptides: Potential New Therapies for Cardiovascular Diseases , 2021, Cells.

[16]  H. Jo,et al.  Recent advances in nanomaterials for therapy and diagnosis for atherosclerosis. , 2021, Advanced drug delivery reviews.

[17]  V. Ramensky,et al.  The LDLR, APOB, and PCSK9 Variants of Index Patients with Familial Hypercholesterolemia in Russia , 2021, Genes.

[18]  K. Socha,et al.  Vitamins in Alzheimer’s Disease—Review of the Latest Reports , 2020, Nutrients.

[19]  Ling Li,et al.  The Role of HDL and HDL Mimetic Peptides as Potential Therapeutics for Alzheimer’s Disease , 2020, Biomolecules.

[20]  Yun Zhang,et al.  A novel apoA‐I mimetic peptide suppresses atherosclerosis by promoting physiological HDL function in apoE−/− mice , 2020, British journal of pharmacology.

[21]  Yang Wang,et al.  Effectiveness of niacin supplementation for patients with type 2 diabetes , 2020, Medicine.

[22]  J. Severens,et al.  European survey on acute coronary syndrome diagnosis and revascularisation treatment: Assessing differences in reported clinical practice with a focus on strategies for specific patient cases , 2020, Journal of evaluation in clinical practice.

[23]  A. Murphy,et al.  Apolipoprotein AI) Promotes Atherosclerosis Regression in Diabetic Mice by Suppressing Myelopoiesis and Plaque Inflammation. , 2019, Circulation.

[24]  Karin Kornmueller,et al.  Artificial High Density Lipoprotein Nanoparticles in Cardiovascular Research , 2019, Molecules.

[25]  E. Fisher,et al.  HDL and Reverse Cholesterol Transport. , 2019, Circulation research.

[26]  C. Wellington,et al.  HDL from an Alzheimer's disease perspective , 2019, Current opinion in lipidology.

[27]  A. Kesselheim,et al.  Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes , 2019, JAMA network open.

[28]  D. Barisani,et al.  APOA-1Milano muteins, orally delivered via genetically modified rice, show anti-atherogenic and anti-inflammatory properties in vitro and in Apoe-/- atherosclerotic mice. , 2018, International journal of cardiology.

[29]  M. Yamagishi,et al.  Mendelian randomization: Its impact on cardiovascular disease. , 2018, Journal of cardiology.

[30]  M. Averna,et al.  Lack of Correlation of Plasma HDL With Fecal Cholesterol and Plasma Cholesterol Efflux Capacity Suggests Importance of HDL Functionality in Attenuation of Atherosclerosis , 2018, Front. Physiol..

[31]  J. Kastelein,et al.  Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial: A Randomized Clinical Trial , 2018, JAMA cardiology.

[32]  J. Kastelein,et al.  Effect of Serial Infusions of CER-001, a Pre-&bgr; High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial: A Randomized Clinical Trial , 2018, JAMA cardiology.

[33]  D. Dichek,et al.  In Vivo Gene Transfer to the Rabbit Common Carotid Artery Endothelium. , 2018, Journal of visualized experiments : JoVE.

[34]  Lawrence A Leiter,et al.  Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract , 2018, European heart journal.

[35]  C. Indolfi,et al.  The Potential Role of Platelet-Related microRNAs in the Development of Cardiovascular Events in High-Risk Populations, Including Diabetic Patients: A Review , 2018, Front. Endocrinol..

[36]  Minghui Wang,et al.  High scavenger receptor class B type I expression is related to tumor aggressiveness and poor prognosis in lung adenocarcinoma , 2018, Medicine.

[37]  F. Kraemer,et al.  SR-B1: A Unique Multifunctional Receptor for Cholesterol Influx and Efflux. , 2018, Annual review of physiology.

[38]  S. Wright,et al.  CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients , 2018, Arteriosclerosis, thrombosis, and vascular biology.

[39]  D. Dichek,et al.  Apolipoprotein A-I ) Vascular Gene Therapy Provides Durable Protection Against Atherosclerosis in Hyperlipidemic Rabbits , 2017 .

[40]  J. Montaner,et al.  Intravenous treatment with human recombinant ApoA-I Milano reduces beta amyloid cerebral deposition in the APP23-transgenic mouse model of Alzheimer's disease , 2017, Neurobiology of Aging.

[41]  A. Keech,et al.  Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial , 2017, The Lancet.

[42]  Lawrence A Leiter,et al.  Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM‐INSULIN randomized trial , 2017, Diabetes, obesity & metabolism.

[43]  F. Chen,et al.  Effects of Anacetrapib in Patients With Atherosclerotic Vascular Disease , 2018 .

[44]  A. von Eckardstein,et al.  HDL cholesterol: reappraisal of its clinical relevance , 2017, Clinical Research in Cardiology.

[45]  G. Dangas,et al.  The role of HDL in plaque stabilization and regression: basic mechanisms and clinical implications , 2016, Coronary artery disease.

[46]  S. Grinspoon,et al.  Inflammation, immune activation, and cardiovascular disease in HIV. , 2016, AIDS.

[47]  Wai Hang Cheng,et al.  Reconstituted high-density lipoproteins acutely reduce soluble brain Aβ levels in symptomatic APP/PS1 mice. , 2016, Biochimica et biophysica acta.

[48]  J. Cummings,et al.  Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer’s disease , 2016, Alzheimer's Research & Therapy.

[49]  H. Kempen,et al.  A single infusion of MDCO-216 (ApoA-1 Milano/POPC) increases ABCA1-mediated cholesterol efflux and pre-beta 1 HDL in healthy volunteers and patients with stable coronary artery disease , 2015, European heart journal. Cardiovascular pharmacotherapy.

[50]  N. Fitz,et al.  Opposing effects of Apoe/Apoa1 double deletion on amyloid-β pathology and cognitive performance in APP mice. , 2015, Brain : a journal of neurology.

[51]  D. Rader,et al.  HDL re-examined , 2015, Current opinion in lipidology.

[52]  J. Genest,et al.  High density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular risk , 2015, BBA clinical.

[53]  L. Gordon,et al.  Synthetic high-density lipoprotein-like nanoparticles as cancer therapy. , 2015, Cancer treatment and research.

[54]  M. Banach,et al.  Effects of established hypolipidemic drugs on HDL concentration, subclass distribution, and function. , 2015, Handbook of experimental pharmacology.

[55]  M. Hassan HPS2-THRIVE, AIM-HIGH and dal-OUTCOMES: HDL-cholesterol under attack , 2014, Global cardiology science & practice.

[56]  Christos G Mihos,et al.  Cardiovascular effects of statins, beyond lipid-lowering properties. , 2014, Pharmacological research.

[57]  D. Rader,et al.  HDL and cardiovascular disease , 2014, The Lancet.

[58]  Sarah Parish,et al.  Effects of extended-release niacin with laropiprant in high-risk patients. , 2014, The New England journal of medicine.

[59]  A. Kontush,et al.  Unraveling the complexities of the HDL lipidome1 , 2013, Journal of Lipid Research.

[60]  H. Mo,et al.  The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics , 2013, Front. Pharmacol..

[61]  K. Hirata,et al.  Pitavastatin increases HDL particles functionally preserved with cholesterol efflux capacity and antioxidative actions in dyslipidemic patients. , 2013, Journal of atherosclerosis and thrombosis.

[62]  P. Gu,et al.  Effect of Ezetimibe on Insulin Secretion in db/db Diabetic Mice , 2012, Experimental diabetes research.

[63]  John Spertus,et al.  Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study , 2012, The Lancet.

[64]  A. Levy,et al.  HDL dysfunction in diabetes: causes and possible treatments , 2012, Expert review of cardiovascular therapy.

[65]  V. Fuster,et al.  Recombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-type). , 2012, Atherosclerosis.

[66]  William Weintraub,et al.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. , 2011, The New England journal of medicine.

[67]  P. Barter,et al.  Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. , 2011, Circulation.

[68]  Bart Lammers,et al.  ATP-binding cassette transporters A1 and G1, HDL metabolism, cholesterol efflux, and inflammation: important targets for the treatment of atherosclerosis. , 2011, Current drug targets.

[69]  L. Ose Pitavastatin: finding its place in therapy , 2011, Therapeutic advances in chronic disease.

[70]  Manabu T. Nakamura,et al.  Synthetic dimyristoylphosphatidylcholine liposomes assimilating into high-density lipoprotein promote regression of atherosclerotic lesions in cholesterol-fed rabbits , 2010, Experimental biology and medicine.

[71]  M. Sinno,et al.  Impact of Medical Therapy on Atheroma Volume Measured by Different Cardiovascular Imaging Modalities , 2010, Cardiology research and practice.

[72]  S. Vaessen,et al.  AAV gene therapy as a means to increase apolipoprotein A-I and high-density lipoprotein- cholesterol levels: Correction of murine apoA-I deficiency , 2009 .

[73]  T. Groen,et al.  Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease , 2009, Neurobiology of Disease.

[74]  N. Pavlidis,et al.  Effects of hormonal treatment on lipids in patients with cancer. , 2009, Cancer treatment reviews.

[75]  C. Cummins,et al.  Liver X receptors as therapeutic targets for managing cholesterol: implications for inflammatory conditions , 2009, Clinical lipidology.

[76]  W. Frishman,et al.  HDL Metabolism and CETP Inhibition , 2008, Cardiology in review.

[77]  R Peto,et al.  Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. , 2008, Lancet.

[78]  D. Rader,et al.  Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent , 2007, Cardiovascular diabetology.

[79]  Judith Wylie-Rosett,et al.  Diet and Lifestyle Recommendations Revision 2006: A Scientific Statement From the American Heart Association Nutrition Committee , 2006, Circulation.

[80]  L. Simons,et al.  Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome , 2004, Current medical research and opinion.

[81]  S. Reddy,et al.  Oral D-4F Causes Formation of Pre-βHigh-Density Lipoprotein and Improves High-Density Lipoprotein–Mediated Cholesterol Efflux and Reverse Cholesterol Transport From Macrophages in Apolipoprotein E–Null Mice , 2004, Circulation.

[82]  Paul Schoenhagen,et al.  Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. , 2003, JAMA.

[83]  Е. П. Корнена,et al.  Cholesterol lowering drugs. , 1993, The New Zealand medical journal.

[84]  J. Hewitt,et al.  The role of lipids and lipoproteins in atherosclerosis. , 1950, Science.